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We have recently shown that thrombin-stimulated 
human platelets have specific, saturable receptors for 
factor IXa, occupancy of which promotes factor X ac- 
tivation (Ahmad, S. S., Rawala-Sheikh, R., and Walsh, 
P. N. (1989) J. Biol. Chem. 264: 3244-3251,20012- 
20016; Rawala-Sheikh, R., Ahmad, S. S., and Walsh, 
P. N. (1990) Biochemistry 29,2606-2611). To study 
the structural requirements for factor IXa binding to 
platelets, equilibrium binding studies and kinetic stud- 
ies of factor X activation were carried out with normal 
factor IXa and with two variant proteins: factor 
IXaAlat,ama (FE&L; Asp”I + Gly substitution) and factor 
IX%hapel Hill (FIXkH; Arg14’ + His substitution). In the 
absence of factors VIIIa and X, there were 331 binding 
sites/platelet for FIXeH (&,,, = 2.8 nM), and 540 sites/ 
platelet for FIXaAL (&,,, = 3.2 nM), compared with 
540 sites/platelet (& app = 2.3 nM) for normal factor 
IXa. The addition of factors VIIIa and X, both at satu- 
rating concentrations, had no effect on the number of 
binding sites for either normal or variant factor IXa, 
resulted in a decrease in the & for normal factor IXa 
to 0.67 nM, resulted in a suboptimal decrease in & for 
FIXaAL (1.4 nM), and had no effect. on the Kd for FIXeH. 
Kinetic studies of factor X activation at variable factor 
IXa concentration confirmed these values of Kd in the 
presence of factors VIIIa and X. Determination of rates 
of factor X activation at variable substrate concentra- 
tions yielded normal values of catalytic efficiency (L/ 
K,) for the variant proteins, thereby indicating that 
the abnormally low rates of factor X activation ob- 
tained were a consequence of the low affinity binding 
of FIXaAL and FIX%” to thrombin-activated platelets 
in the presence of factors VIIIa and X. These studies 
suggest that the presence of Asph7 and the cleavage of 
factor IX at Arg’45-Ala’46 are important structural fea- 
tures required for specific, high affinity factor IXa 
binding to platelets in the presence of factors VIIIa and 
X. 
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Activated human platelets promote the activation of factor 
X by factor IXa (1, 2). Previous studies from our laboratory, 
aimed at elucidating the mechanisms by which platelets and 
factor VIII contribute to this coagulation reaction, have shown 
that thrombin-stimulated human platelets have specific, sat- 
urable binding sites for factor IXa and that the presence of 
factor VIII and factor X increases the binding affinity 5-fold 
(3). We have also shown that platelet receptor occupancy with 
factor IXa is closely correlated with rates of factor X activa- 
tion (4, 5). 
To study the structural requirements for factor IXa binding 
to platelets, we have now carried out detailed comparative 
platelet binding and kinetic studies with normal and variant 
factor IXa molecules. One of these proteins, faCtOr IX,&hrne 
(factor IXAL),l can be activated by factor XIa in the presence 
of calcium ions to a factor IXaB form with about 10% of the 
clotting activity of the normal factor IXaO (6, 7). An adenine 
to guanine transition in the first nucleotide of exon d causes 
the substitution of a glycine codon (GGT) for the normal 
aspartic acid codon (GAT). This point mutation results in a 
single amino acid substitution at residue 47 of the zymogen 
in the first epidermal growth factor-like domain of factor IXAL 
(8). The factor IX defects previously reported in the first 
epidermal growth factor-like domain are mostly associated 
with mild hemophilia B. In addition to factor IXaAL, these 
include factor IXLondon7 (Pro55 + Ala, 10% of normal activity) 
(9), factor IXDurham (Gly6’ + Ser, 14% of normal activity) (lo), 
factor IXLondon,j (P-OH Asp@ + Gly, 8% of normal activity), 
and factor IXN,, b,,don (G1u5’ + Pro, Cl% of normal activity) 
(11). 
The second variant protein we have studied is factor 
I&hap, Hill (factor IX&. The molecular defect in factor IXcH 
is the substitution of histidine for arginine at position 145 
(12-14). This is the first cleavage site in the normal pathway 
of factor IX activation. Thus, factor IXcH is not activated 
normally either by factor XIa or by factor VIIa-tissue factor. 
Only the Arg’80-Va1’81 bond is cleaved giving rise to factor 
IXa,, in which the activation peptide remains covalently 
attached to the light chain. Factor IXacucH has 20% of the 
clotting activity of normal factor IXa@. Mutations in certain 
abnormal factor IX proteins have been demonstrated to cause 
abnormally slow or incomplete activation of factor IX by 
factor XIa. These include defects such as that in factor IXHilo 
in which cleavage of the Arg’80-Va1’81 bond is prevented by 
substitution of glutamine for arginine at position 180. The 
dysfunction of factor IXNewLondon has also been attributed to 
’ The abbreviations used are: factor IXA~, factor IXA~~~~~; factor 
I&X factor I&hapel H~II; factor IXN, normal factor IX; PPACK, D- 
phenylalanyl-prolyl-arginyl chloromethyl ketone; HEPES, 4-(2-hy- 
droxyethyl)-1-piperazineethanesulfonic acid. 
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defective cleavage at the Arg’*“-Val’*’ bond (11). 
The lipid binding and kinetic properties of normal factor 
IXa (factor IXaN) have been examined and compared in detail 
with the two variant proteins, namely factor IXAL and factor 
IXcH (15). In this paper we have carried out detailed studies 
to compare the platelet binding and kinetic studies of these 
abnormal variant factor IXa molecules with factor IXaN. 
electrophoresis in NaDodS04 was carried out according to the pro- 
cedure of Laemmli (17). 
EXPERIMENTAL PROCEDURES 
Materials-D-Phenyi-alanyl-prolyl-arginyl chloromethyl ketone 
(PPACK) was purchased from Behring Diagnostics. The chromogenic 
substrate S2337 (Bz-Ile-Glu-(y-piperidyl)-Gly-Arg-p-nitroanilide) 
was purchased from AB Kabi Diagnostica. Other materials were the 
same as reported previously (3-5). 
Proteins-Details of the purification, assay, and characterization 
of human coagulation proteins, including factor IX, factor IXa, factor 
VIII, factor X, and cu-thrombin, were previously published (3). The 
conditions used for activation of factor VIII were identical with those 
previously published (3-5). The variant factor IX molecules were 
isolated from human plasma as described previously (15). Both the 
normal and variant factor IX molecules were radiolabeled with “‘1 
by the Iodo-Gen method as previously described (3), and specific 
radioactivities of all proteins were in the range of 2.0-2.5 x lo6 cpm/ 
pg. Activation of purified factor IXb, factor IXA,., and factor IX,.-” by 
purified human factor XIa were carried out as previously described 
(3). Autoradiograms of normal and variant factor IX and factor IXa 
were developed to provide structural characterization of “Y-labeled 
proteins. Both l’SI-labeled factor IXA~ and factor IXc” appeared as 
single bands at M, = 57,000 (Fig. 1, lanes 2 and 3) and were indistin- 
guishable from factor IX, (Fig. 1, lane I). Similar results were 
obtained with the zymogens after reduction (Fig. 1, lanes 4,5, and 6). 
Both factor IXap, (Fig. 1, lane 7) and factor IXaAL (lane 8) migrated 
nonreduced at an apparent M, of -45,000, whereas factor IXacH (lane 
9) remained at a M, of 57,000 since the activation peptide remained 
covalently attached to the light chain. After reduction, the ““I-labeled 
factor IXaAI, migrated as two polypeptides of M, = 27,000 and 17,000 
(Fig. 1, lane II), as did factor IXaN (Fig. 1, lane IO), whereas ‘*?- 
labeled factor IXacH appeared under reducing conditions (Fig. 1, lane 
12) as two bands, in addition to a small quantity (8.9% by scanning 
of the autoradiogram), as previously reported (13) of the original 
zymogen. One of the two major bands migrated with a mobility 
identical with that of the heavy chain band from factor IXN, whereas 
the other band had an apparent M, of 45,000 which corresponds to a 
cleavage product consisting of the light chain and the activation 
peptide similar to that found on cleavage of either factor IXN or 
factor IXCH by Russell’s viper venom (13, 16). The clotting activities 
of activated factor IXAL and factor IXc- were 15% and 18%, respec- 
tively, of the clotting activity of factor IXaN. Protein concentrations 
were determined by the Bio-Rad dye binding assay according to 
instructions provided by the manufacturer. Polyacrylamide slab gel 
M, x lo-3 
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FIG. 1. Autoradiogram of normal and variant “‘I-factor IX 
and factor IXa molecules. Autoradiograms are shown of 13% 
polyacrylamide gel electrophoretograms in sodium dodecyl sulfate of 
‘LSI-labeled factor IXh, factor IX AL, and factor IXcH (nonreduced, 
lanes I, 2, and 3; and reduced, lanes 4, 5, and 6, respectively) and 
factor IXaN, factor IXaAI., and factor IXacH (nonreduced, lanes 7, 8, 
and 9 and reduced, lanes 10, II, and 12, respectively). Abbreviations 
are as follows, showing positions of polypeptide chains in the gel: 
IX,, zymogen; Int, intermediate band consisting of light chain and 
activation peptide; HC, heavy chain; LC, light chain. 
Binding Experiments--In a typical binding experiment, gel-filtered 
olatelets (3-4 x 10R/ml) in calcium-free HEPES Tvrode’s buffer. uH 
j.4, were incubated’at 37 “C in a 1.5-ml Eppendorfplastic centrifuge 
tube with mixtures of unlabeled and radiolabeled factor IXa, calcium 
chloride, platelet stimuli, and other proteins. Platelets were separated 
from unbound proteins as previously described (3). The data were 
analyzed and the number of binding sites and dissociation constants 
(&) were calculated from the means of six independent determina- 
tions, each done in duplicate, as previously described (3) using a Mac 
Plus Computer and the LIGAND Program as modified by McPherson 
ea. 
Measurements of Rates of Factor Xa Formation-The activation of 
factor X by normal and variant factor IXa was carried out at 37 “C 
in the presence of thrombin-stimulated gel-filtered platelets, factor 
VIIIa, and calcium chloride as described previously (3-5). The details 
of experimental conditions and concentrations of reactants are given 
unde; “Results” and in the figure legends. 
Calculations of Kinetic Consstunts-The derivation of kinetic con- 
stants of factor X activation by factor IXa was based on a one- 
enzyme, one-substrate model. The Michaelis constant (K,,,) and the 
maximum velocity (V,,,.,) were calculated from the mean + S.E. of 
five independent determinations each done in duplicate of factor X 
activation rates at variable factor X concentrations as described 
previously (5). Values of dissociation constant (&) were obtained 
from experiments in which rates of factor X activation were deter- 
mined ai variable factor IXa concentrations as previously described 
(4). The values of turnover numbers (kc.,) were calculated by dividing 
Vi,. values either by the total factor~ika concentration br by the 
amount of enzyme (factor IXa) bound under the conditions of the 
experiment. This latter value was obtained from the equation: 
B .E 
Amount bound = mar 
Kd + E 
where B,., is the maximum amount of factor IXa hound or the total 
receptor concentration; E, total factor IXa concentration; and Kd, 
dissociation constant. The details of this calculation are provided in 
previous papers (4, 18). 
RESULTS 
Specific Binding of “‘I-Labeled Factor IXaN, Factor IXaal., 
and Factor IXacH to Thrombin-activated Normal Human 
Platelets-In the present work, we have compared binding of 
‘2”I-labeled factor IXa with the binding of factor IXaAL and 
factor IXacH to normal human platelets. Scatchard analysis 
of the binding data (Fig. 2) gave straight lines indicating the 
presence of a single class of binding sites for both the normal 
and variant factor IXa molecules both in the presence and 
absence of factor VIIIa and factor X. The affinity and stoi- 
chiometry of binding for these ligands under both experimen- 
tal conditions was determined in six separate experiments, 
the means (+S.E.) of which are given in Table I. In addition, 
the stoichiometry and affinity of factor IX binding was deter- 
mined as previously reported (3), and the results were re- 
corded in Table I. In the absence of factor VIIIa and factor 
X, there were 331 binding sites/platelet for factor IXacH 
(Kd spp = 2.8 nM) and 540 sites/platelet for factor IXaAL (& app 
= 3.2 nM), compared with 540 sites/platelet (& app = 2.5 nM) 
for factor IXaN, and 306 sites/platelet (Kdapp = 2.6 nM) for 
factor IXN. The addition of factor VIIIa and factor X, both at 
saturating concentrations, had no effect on the number of 
binding sites for either normal or variant factor IXa molecules 
or for factor IXN, resulted in a decrease in the & for factor 
IXaN to 0.67 nM, resulted in a suboptimal decrease in & for 
factor IXaAL (1.4 nM), and bad no effect on the & for either 
factor IXacH or factor IXN. The number of binding sites for 
factor IXaAL was not significantly different from that for 
factor IXaN. The number of binding sites for factor IXacH 
was significantly lower than that for factor IXaN (p < 0.01) 
and was not significantly different from that for factor IXN. 
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FIG. 2. Scatchard analysis of the specific binding of l*‘I- 
factor IXaN, Y-factor IXaAL, and ‘T-factor IXaca to throm- 
bin-stimulated normal human platelets in the absence and 
presence of factor VIII and factor X. Gel-filtered platelets (3.5 x 
lO’/ml) were incubated at 37 “C with human cy-thrombin (0.1 unit/ 
ml), CaClz (5 mM), and ““I-factor IXaN, factor IXaAL, or factor IXacu 
in the presence or absence of thrombin-activated factor VIII (5 units/ 
ml) and factor X (1.5 NM). Binding was determined as detailed under 
“Materials and Methods.” Nonspecific binding was determined in the 
presence of excess unlabeled factor IXa (0.44 pM; 25 fig/ml) and was 
subtracted from total binding to obtain specific binding. The results 
shown represent a Scatchard plot of specific binding data for factor 
IXaN in the absence (0) and presence (0) of factor VIIIa and factor 
X compared with specific binding data for either factor IXaAL (A, A) 
or factor IXacH (Cl, n ) in the absence (A, Cl) or presence (A, n ) of 
factor VIIIa and factor X. The plotted results represent mean values 
from six experiments with normal and variant factor IXa molecules, 
each done in duplicate. 
TABLE I 
Binding constants for normal and variant factor IXa molecules 
Ligand 
Number of Kd 
















540 f 68 2.3 + 0.39 
590 + 60 0.67 -t 0.05 0.61 f 0.02 
540 + 52 3.2 + 0.41 
506 + 47 1.4 + 0.09 1.4 f 0.10 
331 + 44 2.8 f 0.45 
310 + 45 3.0 + 0.51 2.0 f 0.06 
306 f 57 2.6 + 0.25 
316 f 50 2.4 + 0.30 
Kinetic Studies of Normal and Variant Factor IXa-In this 
study we also determined the apparent Kd for normal and 
variant factor IXa binding to platelets by kinetic studies of 
factor Xa formation in the presence of saturating concentra- 
tions of factor X and factor VIIIa (Fig. 3). The kinetic 
approach gave similar results to the binding studies (3, 4), 
and its use is justified in our previous studies (3-5). The 
apparent Kd was determined as 0.61 nM for factor IXan, 1.4 
nM for FIXaAL and 2.0 nM for FIXacH (Fig. 3 and Table I). 
We also determined the kinetic parameters for factor X 
activation by normal and variant factor IXa molecules in the 
presence of thrombin-stimulated platelets and factor VIIIa 
(Fig. 4). Studies were carried out at a factor IXa concentration 
of 0.01 nM, well below the apparent dissociation constant for 
binding of factor IXa to platelets. The values of K,,,, V,.,, k,,,, 
and catalytic efficiency (kJK,,,) for factor IXaN, factor IXaAL 
and factor IXacH obtained at saturating concentrations of 
100 1 -I 
0 1 2 3 4 5 
FIXa 
FIG. 3. Rates of factor Xa formation by normal and variant 
factor IXa in the presence of thrombin-activated platelets and 
factor VIIIa. The rates of activation of human factor X by varying 
concentrations (0.17-5.0 nM) of factor IXa were determined in the 
presence of 5 x lO’/ml thrombin-activated platelets at 37 “C in a 
reaction volume of 100 ~1 containing 50 mM Tris (pH 7.9), 175 mM 
NaCl, 5 mM CaCL, 1.5 pM factor X, 5 units/ml of factor VIIIa, and 
0.5 mg/ml human serum albumin. Platelets were stimulated with 0.1 
unit/ml thrombin in the presence of CaClz (5 mM), and factor IXa 
was preincubated with platelets for 10 min at 37 “C. Excess thrombin 
was neutralized with 50 nM PPACK before the addition of factor 
VIIIa and performance of the assay. For experimental details see 
“Experimental Procedures.” The plotted results for factor IXaN (O), 
factor IXaAL (A), and factor IXacH (U) are the mean f SE. of 
duplicate observations from five separate experiments. 
1 
-I 
200 400 600 600 1001 
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s’ 
FIG. 4. Factor X activation by normal and variant factor 
IXa. Initial rates of factor X activation (mean + S.E.) were deter- 
mined as described under “Experimental Procedures” at various 
concentrations of factor X as indicated in the graph. The experiment 
was carried out essentially as described in the legend to Fig. 3 except 
that factor X concentration was varied and the concentration of 
normal or variant factor IXa was 10 PM. The plotted results for factor 
IXaN (O), factor IXaAL (A), and factor IXacH (W) are the mean + SE. 
of duplicate observations from five separate experiments. 
factor VIIIa are summarized in Table II. Catalytic efficiency 
can be assessed in two ways: 1) as a function of the total 
amount of factor IXa added, or 2) as a function of the amount 
of factor IXa bound to the platelet. If catalytic efficiency is 
assessed as a function of the amount of factor IXa bound, 
there is essentially no difference in the rate at which factor 
X is activated (the last column of Table II). So the decrease 
in the rate at which a given amount of factor IXaAL or factor 
IXacu can catalyze factor X activation is solely due to the 
reduced affinity of these two proteins for the platelet-factor 
VIIIa-factor X complex. 
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TABLE II 
Normal and variant factor ZXa catalyzed factor X activation: kinetic 
analvsis 
PM IlM. min-’ min-’ PM’. min-’ 
Factor IXaN 0.10 18.7 1,870 2,671 18,700 26,714 
Factor IXaAL 0.08 7.4 740 2,633 9,250 32,913 
Factor IXacH 0.18 12.5 1,250 6,621 6,944 36,783 
’ k,., expressed as moles of factor Xa formed per min per mol of 
total added factor IXa. 
b k,., expressed as moles of factor Xa formed per min per mol of 
total platelet-bound factor IXa. 
DISCUSSION 
The purpose of the studies reported here was to begin an 
analysis of the structural features of the factor IXa molecule 
that are important for factor IXa binding to platelets and for 
the assembly of the factor X activating complex on the platelet 
surface. Previously we have shown that factor IXa binds 
reversibly to 500-600 sites per platelet and that platelet 
activation and the presence of calcium ions are required for 
this interaction (3). The dissociation constant (I&) for factor 
IXa binding to activated platelets is -2.5 nM in the absence 
of factor VIIIa and factor X and -0.5 nM in the presence of 
these proteins at saturating concentrations (3). Similar find- 
ings have been reported for bovine aortic endothelial cells by 
Stern et al. (19). We have also shown that zymogen factor IX 
binds to 250-300 sites per activated platelet in the presence 
of calcium ions with a & of -2.5 nM either in the presence 
or absence of factors VIIIa and X and that factor IX competes 
with factor IXa for about one-half its low affinity sites in the 
presence of factors VIIIa and X (3). This suggests that the 
zymogen contains a domain important for binding of the 
enzyme to its platelet receptor and that the conversion of 
factor IX to factor IXa involves either a conformational 
alteration or the exposure of domains in factor IXa that allow 
it to interact with twice the number of platelet receptors as 
factor IX and also allow it to interact with factors VIIIa and 
X. We have further demonstrated that factor IXa binding to 
its high affinity site is closely correlated with rate enhance- 
ments of factor X activation by activated platelets (4), which 
can decrease the K, for factor X activation and can permit 
factor VIIIa to increase the kCat with a consequent increase of 
catalytic efficiency (k,,t/K,,,) of (17.4 x 106)-fold (5). Finally, 
we have studied the role of the active site of factor IXa in the 
binding of the enzyme to platelets by examining the interac- 
tion with platelets of factor IXa active site inhibited with 
dansyl-L-glutamyl-glycyl-L-arginyl chloromethyl ketone 
(DEGR-CK). Since DEGR-factor IXa was shown to be a 
competitive inhibitor both of factor IXa binding and of factor 
X activation, with a Ki almost identical with the & for factor 
IXa binding, we concluded that the active site of factor IXa 
is not involved in binding to the high affinity site in the 
presence of factor VIIIa and factor X (4). 
To determine the structural features of factor IXa that are 
required for interaction with platelet receptors and for assem- 
bly of the factor X activating complex, we studied the binding 
of factor IXaAL and factor IXacn to activated platelets. It has 
previously been suggested (16, 20) that the abnormal coagu- 
lant activities of these two proteins could be a consequence of 
deficient binding to charged membrane surfaces. However, it 
was subsequently shown (15) that the abnormal rates of factor 
X activation observed with both factor IXaAL and factor IXacn 
in the presence of small, unilamellar vesicles composed of 
30% phosphatidylserine and 70% phosphatidylcholine were 
not a consequence of abnormal binding. Thus, the zymogen 
and activated forms of factor IXN, factor IXAL, and factor 
IXcn were shown to bind with similar affinities to small, 
unilamellar vesicles as determined by 90” light scattering (15). 
It was therefore concluded that the normal function of factor 
IXa must entail interactions between the light and heavy 
chains on the phospholipid surface. 
The present studies addressed the structural requirements 
for binding of factor IXa to what must be presumed the 
physiologic locus of factor X activation, i.e. the platelet mem- 
brane. Factor IXaAL was shown to bind with normal affinity 
(I& = 3.2 nM) to a normal number (540) of sites per platelet 
in the absence of factors VIIIa and X. This implies that the 
aspartic acid residue at position 47 in the normal protein (and 
mutated to a glycine in factor IX.& is not required for normal 
binding of factor IXa to its platelet receptor. This demonstra- 
tion of a normal affinity of factor IXaAL binding to platelet 
membranes in the absence of factors VIII and X confirms the 
results of Jones et al. (15) showing normal binding of factor 
IXaAL to phospholipid membranes. However, in the presence 
of factors VIIIa and X, the binding affinity of factor IXaAL 
was reduced (& = 1.4 nM) as determined either by equilibrium 
binding or by kinetic determinations of rates of factor X 
activation (Table I). This result is not in conflict with those 
of Jones et al. (15) since their phospholipid binding studies 
were carried out only in the absence of factors VIII and X. 
The results of our kinetic analysis of factor X activation by 
factor IXaAL (Table II) help to clarify the interpretation of 
our binding studies and are also in general agreement with 
the previous factor X activation studies of Jones et al. (15). 
Thus, we found the I& for factor X activation by factor IXaAL 
to be normal, suggesting that factor X binds with normal 
affinity to the factor IXaAL-factor VIIIa-platelet membrane 
complex. The Vmax (7.4 nM . min-‘) with factor IXaAL was 40% 
of normal, i.e. when compared with normal factor IXa (18.7 
nM . min-‘), a result consistent with the reduction in relative 
rate of factor X activation by factor IXaAL (43% of normal) 
obtained by Jones et al. (15) with phospholipids. In the present 
study, however, since we carried out both equilibrium binding 
studies in parallel with factor X activation studies, we were 
able to calculate true catalytic constants ( kC,,J expressing the 
maximal rate of factor Xa formation as a function of the 
amount of factor IXa bound (Table II). The result of this 
analysis demonstrates a normal turnover number (k,,J and 
catalytic efficiency (k,,/K,) for factor IXaAL compared with 
factor IXaN, indicating that the defect in factor X activation 
by factor IXaAL is entirely a consequence of its decreased 
affinity for platelet receptors in the presence of factor VIIIa. 
Therefore, although the interpretation of the molecular basis 
for the defect is open to further study, it would appear that 
the Asp47 ---f Gly mutation in factor IXAL results in a decreased 
rate of factor X activation solely as a consequence of decreased 
affinity of the mutant enzyme for its platelet receptor in the 
presence of factor VIIIa and factor X. 
A recent paper published by McCord et al. (21) reporting 
studies with factor IXAL provides evidence for a conforma- 
tional change in factor IX due to high affinity calcium binding 
in the first epidermal growth factor domain. These authors 
found that although factor IXAL binds calcium ions normally 
to a high affinity site in the first epidermal growth factor 
domain, the variant enzyme fails to undergo a calcium-in- 
duced conformational change that occurs in normal factor 
IXa, thereby permitting it to interact properly with factor 
VIIIa and factor X. Thus, whereas factor IXAL was activated 
normally by factor XIa and factor IXaAi. had 52-60% of 
normal activity in a calcium/phospholipid vesicle system, the 
addition of factor VIIIa decreased the relative rate of factor 
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X activation by factor IXaAL to 18-19% of normal. These 
observations are consistent with our suggestion that the defect 
in factor IXaAL is a consequence of its failure to bind with 
normal affinity to membranes in the presence of factor VIIIa. 
Our studies with factor IXacu show that this variant en- 
zyme binds to platelets in a manner indistinguishable from 
normal zymogen factor IX (Table I). Thus, the number of 
binding sites per activated platelet appears to be similar to 
that for normal factor IX and about half the number for 
normal factor IXa. Moreover, the affinity of binding, which 
is 5-fold enhanced for normal factor IXa in the presence of 
factors VIIIa and X, is unaffected by factors VIIIa and X in 
the case of factor IXacH. This very interesting result suggests 
that cleavage of factor IX at Arg’45-Ala’46 (defective in factor 
IXcH because of the Arg’45 -+ His substitution), as well as at 
Arg’80-Val’8’, with consequent formation of an activation pep- 
tide, is required for binding to the normal complement of 
receptors. In attempting to explain why the number of binding 
sites for factor IXa is almost exactly double that for zymogen 
factor IX, it is tempting to speculate that the receptor is 
bivalent (possibly homodimeric) and can accommodate two 
factor IXa molecules but only one factor IX molecule. It is 
possible that the presence of the heavily glycosylated activa- 
tion peptide region of factor IX prevents access of a second 
factor IX molecule to the receptor complex, whereas forma- 
tion of the activation peptide or its release from covalent 
attachment allows the resultant factor IXa access to both 
binding sites on the putative dimeric receptor. The fact that 
the affinity of factor IXacH for platelets is unaffected by the 
presence of factors VIIIa and X suggests that cleavage of 
factor IXa at Arg’45-Ala’46 is essential for the exposure in 
factor IXa of a binding site for the factor VIIIa-factor X 
complex that is involved in high affinity binding of factor IXa 
to platelets. 
The present studies that demonstrate a normal affinity of 
factor IXacu binding to activated platelets in the absence of 
factors VIII and X are in agreement with the demonstration 
by Jones et al. (15) of normal binding of factor IXacH to 
phospholipid (phosphatidylserine/phosphatidylcholine) vesi- 
cles by 90” light scattering. Our demonstration that factor 
IXacH fails to bind to activated platelets with high affinity in 
the presence of factors VIIIa and X is not inconsistent with 
the phospholipid binding studies of Jones et al. (15) which 
were not done in the presence of factors VIII and X. Finally, 
the present studies demonstrating abnormally low rates of 
factor X activation by factor IXacH are entirely consistent 
with the studies of Jones et al. (15). Thus, as shown in Table 
II, the catalytic efficiency (k,,&,,) calculated for factor IXacH 
in the presence of activated platelets and factor VIIa was 
6,944 @K’ .min-’ or 37% of normal (18,700 PM-‘. mini) when 
the k,., was based on the total amount of enzyme added, 
compared with a relative rate of factor X activation by factor 
IXacH shown to be 36% of normal by Jones et al. (15). 
However, when we calculated k,,, as moles of factor Xa formed 
per mol of factor IXa bound, the catalytic efficiency proved 
to be essentially normal (36,783 min-’ compared with 26,714 
min-’ for normal factor IXa). This indicates that the defect 
in factor X activation observed with factor IXacH is attribut- 
able solely to the decreased amount and affinity of factor 
IXacH binding to platelets in the presence of factors VIIIa 
and X. 
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